聚乙二醇化干扰素α-2a时代原发性血小板增多症女性的妊娠结局：卡塔尔的经验
Outcome of Pregnancy in the Era of Pegylated Interferon Alpha 2a in Females with Essential Thrombocythemia: An Experience from Qatar.
作者信息
Abu-Tineh Mohammad, Kassem Nancy, Abdulla Mohammad Abdul-Jaber, Ismail Omar Mohammad, Ghasoub Rola, Aldapt Mahmood B, Yassin Mohamed A
机构信息
Department of Medical Education, Hamad Medical Corporation (HMC), Doha, Qatar.
National Center for Cancer Care and Research, Department of Pharmacy, HMC, Doha, Qatar.
出版信息
Case Rep Oncol. 2020 Mar 26;13(1):336-340. doi: 10.1159/000506447. eCollection 2020 Jan-Apr.
Abstract
Myeloproliferative neoplasms are a diversified group of diseases of the hematopoietic stem cell, such as essential thrombocythemia (ET) and polycythemia vera. They are mainly caused by mutations in the following genes: and . All carry an increased risk to transform into acute leukemia or chronic myelogenous leukemia along with thrombosis and hemorrhagic complications. Treatment of such disorders during pregnancy is a challenging footstep, given the high risk of complications for both the mother and the fetus. Here, we report about two pregnant females with ET that has been treated with pegylated interferon alpha with safe and effective outcome.
摘要
骨髓增殖性肿瘤是造血干细胞的一组多样化疾病，如原发性血小板增多症（ET）和真性红细胞增多症。它们主要由以下基因的突变引起： 和 。所有这些疾病都有转化为急性白血病或慢性粒细胞白血病的风险增加，同时伴有血栓形成和出血并发症。鉴于对母亲和胎儿都有很高的并发症风险，孕期治疗此类疾病是具有挑战性的一步。在此，我们报告两例患有ET的孕妇，她们接受了聚乙二醇化干扰素α治疗，结果安全有效。
相似文献
1
Outcome of Pregnancy in the Era of Pegylated Interferon Alpha 2a in Females with Essential Thrombocythemia: An Experience from Qatar.
Case Rep Oncol. 2020 Mar 26;13(1):336-340. doi: 10.1159/000506447. eCollection 2020 Jan-Apr.
2
Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
Am J Hematol. 2017 Jan;92(1):94-108. doi: 10.1002/ajh.24607.
3
JAK2, CALR, and MPL Mutation Profiles in Colombian patients with BCR-ABL Negative Myeloproliferative Neoplasms.
Colomb Med (Cali). 2023 Sep 30;54(3):e2035353. doi: 10.25100/cm.v54i3.5353. eCollection 2023 Jul-Sep.
4
Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management.
Am J Hematol. 2024 Apr;99(4):697-718. doi: 10.1002/ajh.27216. Epub 2024 Jan 25.
5
Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.
J Clin Oncol. 2009 Nov 10;27(32):5418-24. doi: 10.1200/JCO.2009.23.6075. Epub 2009 Oct 13.
6
Comparison of Clinical and Hematological Parameters of Janus Kinase 2, Calreticulin or Myeloproliferative Leukemia Virus Oncogene Mutant Essential Thrombocythemia and Triple-Negative Essential Thrombocythemia.
Cureus. 2022 Mar 15;14(3):e23171. doi: 10.7759/cureus.23171. eCollection 2022 Mar.
7
CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
Am J Clin Pathol. 2015 May;143(5):635-44. doi: 10.1309/AJCPUAAC16LIWZMM.
8
JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.
Blood. 2014 Mar 6;123(10):1544-51. doi: 10.1182/blood-2013-11-539098. Epub 2013 Dec 23.
9
Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management.
Am J Hematol. 2020 Dec;95(12):1599-1613. doi: 10.1002/ajh.26008. Epub 2020 Oct 23.
10
Pegylated interferon alpha - 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial.
Leuk Res. 2017 Mar;54:73-77. doi: 10.1016/j.leukres.2017.01.006. Epub 2017 Jan 5.
引用本文的文献
1
Contraception in Myeloproliferative Neoplasms: A Pharmacological Review.
Eur J Haematol. 2025 Oct;115(4):344-348. doi: 10.1111/ejh.70014. Epub 2025 Jul 28.
2
Molecular Mechanisms Determining Mammalian Oocyte Quality with the Treatment of Cancer Therapy.
Adv Anat Embryol Cell Biol. 2024;238:97-119. doi: 10.1007/978-3-031-55163-5_5.
3
Outcomes of the Pregnancies with Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era and Literature Review.
Hematol Rep. 2022 Mar 20;14(1):45-53. doi: 10.3390/hematolrep14010008.
本文引用的文献
1
Pregnancy outcomes, risk factors, and cell count trends in pregnant women with essential thrombocythemia.
Leuk Res. 2020 Nov;98:106459. doi: 10.1016/j.leukres.2020.106459. Epub 2020 Sep 29.
2
Clinical Exome Sequencing unravels new disease-causing mutations in the myeloproliferative neoplasms: A pilot study in patients from the state of Qatar.
Gene. 2019 Mar 20;689:34-42. doi: 10.1016/j.gene.2018.12.009. Epub 2018 Dec 13.
3
Pegylated interferon alpha-2a for essential thrombocythemia during pregnancy: outcome and safety. A case series.
Haematologica. 2016 May;101(5):e182-4. doi: 10.3324/haematol.2015.139691. Epub 2016 Jan 27.
4
Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations.
Blood. 2015 Dec 10;126(24):2585-91. doi: 10.1182/blood-2015-07-659060. Epub 2015 Oct 20.
5
Experience with pegylated interferon α-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients.
Haematologica. 2012 Oct;97(10):1570-3. doi: 10.3324/haematol.2011.061390. Epub 2012 Mar 14.
6
The renaissance of interferon therapy for the treatment of myeloid malignancies.
Blood. 2011 May 5;117(18):4706-15. doi: 10.1182/blood-2010-08-258772. Epub 2011 Mar 9.
7
Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.
J Clin Oncol. 2009 Nov 10;27(32):5418-24. doi: 10.1200/JCO.2009.23.6075. Epub 2009 Oct 13.
8
Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms.
Leukemia. 2008 Nov;22(11):1990-8. doi: 10.1038/leu.2008.280. Epub 2008 Oct 9.
9
Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera.
Blood. 2008 Oct 15;112(8):3065-72. doi: 10.1182/blood-2008-03-143537. Epub 2008 Jul 23.
10
A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life.
Cancer. 2006 Jun 1;106(11):2397-405. doi: 10.1002/cncr.21900.
Zotero 插件